SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) Apr 2, 2025 01:36PM
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Allakos Inc. Buyout Apr 2, 2025 12:54PM
Allakos (ALLK) Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share Apr 2, 2025 08:00AM
Allakos (ALLK) Halted, News Pending Apr 2, 2025 07:59AM
Allakos Inc. (ALLK) PT Lowered to $0.40 at Jefferies Jan 27, 2025 12:56PM


Jan 27, 2025 07:01AM Allakos (ALLK) will discontinue further development of AK006
Jan 27, 2025 06:56AM Allakos (ALLK) Halted, News Pending
Nov 7, 2024 09:04AM Allakos (ALLK) Tops Q3 EPS by 4c
Oct 11, 2024 08:42AM TD Cowen Reiterates Hold Rating on Allakos Inc. (ALLK)
Oct 11, 2024 08:05AM Piper Sandler Reiterates Overweight Rating on Allakos Inc. (ALLK)
Oct 10, 2024 04:02PM Allakos (ALLK) Reports Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Aug 8, 2024 03:49AM Allakos (ALLK) Tops Q2 EPS by 3c
Jun 26, 2024 09:15AM TD Cowen Reiterates Hold Rating on Allakos Inc. (ALLK)
Jun 26, 2024 08:12AM Piper Sandler Reiterates Overweight Rating on Allakos Inc. (ALLK)
Jun 25, 2024 04:02PM Allakos (ALLK) Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers